Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures

被引:201
作者
Zhou, Zheng [2 ]
Zhen, Juan [1 ,3 ]
Karpowich, Nathan K. [2 ]
Law, Christopher J. [2 ]
Reith, Maarten E. A. [1 ,3 ]
Wang, Da-Neng [2 ]
机构
[1] NYU, Sch Med, Dept Psychiat, New York, NY 10012 USA
[2] NYU, Sch Med, Dept Cell Biol, Kimmel Ctr Biol & Med,Skirball Inst Biomol Med, New York, NY 10016 USA
[3] NYU, Sch Med, Dept Pharmacol, New York, NY USA
关键词
BIOGENIC-AMINE TRANSPORTERS; HIGH-AFFINITY; BACTERIAL HOMOLOG; BINDING-SITE; NEUROTRANSMITTER; SUBSTRATE; INHIBITOR; FLUOXETINE; REUPTAKE; DRUG;
D O I
10.1038/nsmb.1602
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sertraline and fluoxetine are selective serotonin re-uptake inhibitors (SSRIs) that are widely prescribed to treat depression. They exert their effects by inhibiting the presynaptic plasma membrane serotonin transporter (SERT). All SSRIs possess halogen atoms at specific positions, which are key determinants for the drugs' specificity for SERT. For the SERT protein, however, the structural basis of its specificity for SSRIs is poorly understood. Here we report the crystal structures of LeuT, a bacterial SERT homolog, in complex with sertraline, R-fluoxetine or S-fluoxetine. The SSRI halogens all bind to exactly the same pocket within LeuT. Mutation at this halogen-binding pocket (HBP) in SERT markedly reduces the transporter's affinity for SSRIs but not for tricyclic antidepressants. Conversely, when the only nonconserved HBP residue in both norepinephrine and dopamine transporters is mutated into that found in SERT, their affinities for all the three SSRIs increase uniformly. Thus, the specificity of SERT for SSRIs is dependent largely on interaction of the drug halogens with the protein's HBP.
引用
收藏
页码:652 / U96
页数:7
相关论文
共 49 条
[1]   Characterization of a functional bacterial homologue of sodium-dependent neurotransmitter transporters [J].
Androutsellis-Theotokis, A ;
Goldberg, NR ;
Ueda, K ;
Beppu, T ;
Beckman, ML ;
Das, S ;
Javitch, JA ;
Rudnick, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (15) :12703-12709
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]  
Baldessarini R.J., 2005, Goodman Gilman?s, The Pharmacological Basis of Therapeutics, V11th, P429
[4]  
Barker EL, 1996, MOL PHARMACOL, V50, P957
[5]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[6]   The absolute configuration of sertraline (Zoloft) hydrochloride [J].
Caruso, F ;
Besmer, A ;
Rossi, M .
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 1999, 55 :1712-1714
[7]   Cloning and expression of the mouse serotonin transporter [J].
Chang, AS ;
Chang, SM ;
Starnes, DM ;
Schroeter, S ;
Bauman, AL ;
Blakely, RD .
MOLECULAR BRAIN RESEARCH, 1996, 43 (1-2) :185-192
[8]   Aspartate 345 of the dopamine transporter is critical for conformational changes in substrate translocation and cocaine binding [J].
Chen, NH ;
Rickey, J ;
Berfield, JL ;
Reith, MEA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (07) :5508-5519
[9]   From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: Synthesis and structure-activity relationship studies [J].
Eildal, Jonas N. N. ;
Andersen, Jacob ;
Kristensen, Anders S. ;
Jorgensen, Anne Marie ;
Bang-Andersen, Benny ;
Jorgensen, Morten ;
Stromgaard, Kristian .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (10) :3045-3048
[10]   Coot:: model-building tools for molecular graphics [J].
Emsley, P ;
Cowtan, K .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2004, 60 :2126-2132